The prevalence of non-alcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH), is increasing in parallel to the rising rates of obesity and type II diabetes (T2DM). Currently, about 25% of adults globally are diagnosed with liver steatosis and this number is predicted to increase. Early prevention, identification, and management of liver steatosis, inflammation, and/or fibrosis that ensue, may also contribute to the early prevention of several major cardiometabolic implications (e.g., T2DM) and chronic diseases such as cardiovascular disease (CVD), which is the main cause of morbidity and mortality among individuals diagnosed with NASH.
Lifestyle changes remain the first-line treatment for NASH, even if the optimal treatment is still controversial. Emphasis is mostly put on weight loss but the sustainability of hypocaloric diets is low. Thereby, promoting healthy, dietary patterns rich in bioactives (such as polyphenols) with anti-inflammatory and antioxidant properties is seen as a potentially effective solution.
The aim of this Research Topic is to gather the latest findings on the role of a priori or a posteriori defined dietary patterns and bioactive compounds on NAFLD and/or NASH prevalence and/or progression, as well as their interaction with major cardiometabolic diseases. Manuscripts (reviews, systematic literature review, original research, and case studies) that focus on specific macronutrients, micronutrients, and bioactive compounds will be also considered.
The prevalence of non-alcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH), is increasing in parallel to the rising rates of obesity and type II diabetes (T2DM). Currently, about 25% of adults globally are diagnosed with liver steatosis and this number is predicted to increase. Early prevention, identification, and management of liver steatosis, inflammation, and/or fibrosis that ensue, may also contribute to the early prevention of several major cardiometabolic implications (e.g., T2DM) and chronic diseases such as cardiovascular disease (CVD), which is the main cause of morbidity and mortality among individuals diagnosed with NASH.
Lifestyle changes remain the first-line treatment for NASH, even if the optimal treatment is still controversial. Emphasis is mostly put on weight loss but the sustainability of hypocaloric diets is low. Thereby, promoting healthy, dietary patterns rich in bioactives (such as polyphenols) with anti-inflammatory and antioxidant properties is seen as a potentially effective solution.
The aim of this Research Topic is to gather the latest findings on the role of a priori or a posteriori defined dietary patterns and bioactive compounds on NAFLD and/or NASH prevalence and/or progression, as well as their interaction with major cardiometabolic diseases. Manuscripts (reviews, systematic literature review, original research, and case studies) that focus on specific macronutrients, micronutrients, and bioactive compounds will be also considered.
